• to decrease the chance of critical cardiovascular (coronary heart and blood vessel) complications in adults with form two diabetes and cardiovascular diseaseIn October 2024, Novo Nordisk revealed a examine on scientific journal Mother nature about a novel glucose-sensitive insulin NNC2215 that can lower the risk of hypoglycemia in animal models